Something is happening inside your employee population right now — and the window to get ahead of it is narrowing.

GLP-1 medications like semaglutide and tirzepatide have moved from niche diabetes treatments to mainstream weight loss solutions practically overnight. The demand signal is unmistakable. According to HealthJoy’s 2026 Member Health Goals report, nearly 60% of members have expressed weight loss intent. That’s not a fringe population. That’s the majority of your workforce quietly calculating whether their benefits will cover what they want and what their providers are increasingly willing to prescribe.

The gap between employee demand and a structured employer response is where the real financial and clinical risks live. And for many employers, that gap is still wide open.

The Policy Vacuum Most Employers Don’t Know They Have

When GLP-1s first emerged as a weight loss tool, most employers made a binary decision: cover or don’t cover. That framework made sense when utilization was low and the drugs were new, but in 2026, it no longer does.

Today, GLP-1 prescriptions are accelerating across primary care, telehealth, and other specialty settings, and not always with the clinical rigor the medications truly require. Without a formal coverage policy that defines who qualifies, under what conditions, and with what ongoing oversight is required, employers are effectively leaving the door open to unstructured prescribing that carries real clinical and financial consequences.

What does that look like in practice? A member with a BMI just over the clinical threshold gets a GLP-1 prescription via a telehealth visit with no lab work, no mental health assessment, and no follow-up plan. The drug gets filled. The claim gets paid. That cycle repeats at a cost that can easily exceed $25,000 per member annually, without any mechanism to evaluate whether the treatment is clinically appropriate, working, or sustainable.

This isn’t a hypothetical. It’s a pattern we’re seeing in benefits data across our employer clients, and it’s one of the clearest signals in our latest report. The employers who will face the most severe pharmacy budget pressure aren’t those who chose to cover GLP-1s. They’re the ones who covered them without a framework.

The Shadow Population: What DTC GLP-1s Mean for Employer Risk 

A meaningful share of your workforce may already be on GLP-1 medications and it may not be showing up in your claims data.

The direct-to-consumer GLP-1 market has expanded rapidly, with platforms offering semaglutide and tirzepatide at lower out-of-pocket costs than brand-name alternatives, often without the clinical oversight responsible prescribing requires. For members who want access but face coverage barriers on their employer plan, the DTC pathway is a few clicks away.

The result is a shadow utilization problem. The member is on a GLP-1. The employer doesn't know. And when that member eventually escalates — due to a side effect, an unscreened comorbidity, or weight re-gain after discontinuation — the cost lands back on the employer's plan without any of the upstream clinical infrastructure that could have prevented it.

A GLP-1 policy that only manages on-plan prescribing is only managing part of the population. The employers building the most durable frameworks are asking how to bring DTC users into a structured clinical pathway, through navigation support or incentive design, rather than assuming the problem doesn't exist because it isn't appearing in claims data. Because by the time it does, the window for proactive intervention has already closed.

The $25,000 Problem Is Also a $25,000 Opportunity

The sticker shock around GLP-1 costs is real. Retail pricing for branded medications like Wegovy and Zepbound can run $1,300 to $1,500 per month before any employer-negotiated discounts. Even with rebates and formulary management, per-member annual costs in the $20,000–$25,000 range are common for members without the appropriate clinical guardrails. 

But here’s what the cost conversation misses: not all GLP-1 spend is equal. A member who starts a GLP-1, achieves meaningful weight loss, reduces their cardiovascular risk profile, avoids a diabetes diagnosis, and reduces downstream utilization is a very different financial story than a member who starts a GLP-1, sees modest results, discontinues within six months, and returns to baseline health risk. Both cost the same in the short term. The difference is what happens next, and that difference is almost entirely determined by whether clinical oversight and lifestyle support were part of the picture from day one.

This is the reframe that should anchor every GLP-1 strategy: the question isn’t whether GLP-1s are too expensive. It’s whether your current approach is structured to generate the outcomes that justify the investment.

What a Structured Framework Actually Requires

Building a GLP-1 policy that holds up through your next renewal — and the one after that — isn’t about complete restriction. It’s about precision. Employees want and expect access to these medications, but it takes careful planning to do it right. Here’s what that looks like across several dimensions:

Defined Eligibility Criteria

Employers need to move beyond blanket “we cover weight loss medications” statements, and establish clear clinical thresholds for access. That means specifying BMI requirements (typically 30+ or 27+ with a qualifying comorbidity like hypertension or type 2 diabetes), requiring documentation of prior weight management attempts, and, where appropriate, building in a requirement for physician or care navigator referral.

Prior authorization tied to documented eligibility criteria isn’t gatekeeping, it’s the clinical infrastructure that separates appropriate prescribing from demand-driven prescribing.

Ongoing Clinical Monitoring

GLP-1 therapy isn’t a one-time benefit event. It’s an ongoing clinical relationship that requires regular check-ins, lab monitoring, and dose management. Employers whose benefit programs include mandatory follow-up touchpoints see meaningfully better adherence and outcomes than those who cover the drug without continuity requirements or clinical oversight. 

This is where integrated navigation and a Benefits Operating System plays a critical role. When members have access to a care team that proactively monitors their GLP-1 journey — flagging side effects, coordinating with prescribers, and connecting members to additional resources — the clinical picture improves. So does retention on therapy, which matters because members who discontinue GLP-1s without establishing sustainable lifestyle habits often regain weight and return to higher-risk health profiles.

Integrated Metabolic Health Support

The clinical evidence is consistent: GLP-1s work best when paired with behavioral and lifestyle intervention. Nutrition counseling, physical activity support, and mental health resources aren’t nice-to-haves in a GLP-1 program, they’re the infrastructure that converts short-term weight loss into long-term metabolic health improvement.

Employers building for 2027 should be evaluating whether their benefits ecosystem connects GLP-1 therapy to these adjacent resources, and whether members can actually navigate to them without significant friction. A drug benefit that exists in isolation from the rest of your health ecosystem isn’t a program, it’s an expense.

Why Renewal Season 2027 Is the Deadline That Matters

HealthJoy’s 2026 Member Health Goals report identified GLP-1 spend as one of the primary drivers of benefits cost volatility in the near term — not because the drugs are inherently unmanageable, but because most employers are currently operating without the policy infrastructure to manage them.

The employers who will have the most leverage in their 2027 carrier and PBM negotiations are the ones who can demonstrate structured utilization — defined eligibility, documented clinical pathways, outcome tracking, and evidence of integrated support. That’s the profile that could earn better rebate arrangements, more favorable formulary positioning, and stronger actuarial assumptions in your renewal.

The employers who arrive at renewal with unmanaged GLP-1 spend and no clinical framework will face a different conversation: one driven by their PBM’s risk model rather than their own data. The window to build that framework is now, before utilization scales further, before budget pressure forces reactive rather than strategic decisions, and before the next renewal cycle closes.

GLP-1s are not going away. Demand will continue to rise. The policy gap is closable — but only if employers take action before utilization scales beyond what reactive decisions can manage.

Want to see the full data on GLP-1s and other high cost claim early warning signs? 

Download the 2026 Member Health Goals Report